C Betterle1, F Presotto2,3, J Furmaniak4. 1. Endocrine Unit, Department of Medicine (DIMED), University of Padova, Via Ospedale Civile 105, 35128, Padua, Italy. 2. Endocrine Unit, Department of Medicine (DIMED), University of Padova, Via Ospedale Civile 105, 35128, Padua, Italy. fabio.presotto@unipd.it. 3. Unit of Internal Medicine, Ospedale dell'Angelo, via Paccagnella 11, 30174, Mestre-Venice, Italy. fabio.presotto@unipd.it. 4. FIRS Laboratories, Llanishen, Cardiff, UK.
Abstract
BACKGROUND: Addison's disease (AD) is a rare disorder and among adult population in developed countries is most commonly caused by autoimmunity. In contrast, in children genetic causes are responsible for AD in the majority of patients. PURPOSE: This review describes epidemiology, pathogenesis, genetics, natural history, clinical manifestations, immunological markers and diagnostic strategies in patients with AD. Standard care treatments including the management of patients during pregnancy and adrenal crises consistent with the recent consensus statement of the European Consortium and the Endocrine Society Clinical Practice Guideline are described. In addition, emerging therapies designed to improve the quality of life and new strategies to modify the natural history of autoimmune AD are discussed. CONCLUSIONS: Progress in optimizing replacement therapy for patients with AD has allowed the patients to lead a normal life. However, continuous education of patients and health care professionals of ever-present danger of adrenal crisis is essential to save lives of patients with AD.
BACKGROUND: Addison's disease (AD) is a rare disorder and among adult population in developed countries is most commonly caused by autoimmunity. In contrast, in children genetic causes are responsible for AD in the majority of patients. PURPOSE: This review describes epidemiology, pathogenesis, genetics, natural history, clinical manifestations, immunological markers and diagnostic strategies in patients with AD. Standard care treatments including the management of patients during pregnancy and adrenal crises consistent with the recent consensus statement of the European Consortium and the Endocrine Society Clinical Practice Guideline are described. In addition, emerging therapies designed to improve the quality of life and new strategies to modify the natural history of autoimmune AD are discussed. CONCLUSIONS: Progress in optimizing replacement therapy for patients with AD has allowed the patients to lead a normal life. However, continuous education of patients and health care professionals of ever-present danger of adrenal crisis is essential to save lives of patients with AD.
Entities:
Keywords:
Addison’s disease; Autoimmune polyendocrine syndromes; Natural history of Addison’s disease; Primary adrenal insufficiency; Therapy of Addison’s disease
Authors: Leonie H A Broersen; Alberto M Pereira; Jens Otto L Jørgensen; Olaf M Dekkers Journal: J Clin Endocrinol Metab Date: 2015-04-06 Impact factor: 5.958
Authors: F Ceccato; M Torchio; I Tizianel; M Peleg Falb; M Barbot; C Sabbadin; C Betterle; C Scaroni Journal: J Endocrinol Invest Date: 2022-08-10 Impact factor: 5.467
Authors: Lisette van Alewijk; Kirsten Davidse; Karlijn Pellikaan; Judith van Eck; Anita C S Hokken-Koelega; Theo C J Sas; Sabine Hannema; Aart J van der Lely; Laura C G de Graaff Journal: Endocr Connect Date: 2021-04-22 Impact factor: 3.335
Authors: Haoyang Wang; Karen Feghali; Vybhav A Jetty; Artem Astsaturov; Darren M Evanchuk; Uyen Lam; Ann T Sweeney Journal: AACE Clin Case Rep Date: 2021-05-21
Authors: S Puglisi; A Rossini; I Tabaro; S Cannavò; F Ferrau'; M Ragonese; G Borretta; M Pellegrino; F Dughera; A Parisi; A Latina; A Pia; M Terzolo; G Reimondo Journal: J Endocrinol Invest Date: 2020-08-10 Impact factor: 4.256
Authors: Andrea Crafa; Aldo E Calogero; Rossella Cannarella; Laura M Mongioi'; Rosita A Condorelli; Emanuela A Greco; Antonio Aversa; Sandro La Vignera Journal: Front Endocrinol (Lausanne) Date: 2021-06-16 Impact factor: 5.555